Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Treasury Shares (2016 - 2025)

Avanos Medical's Treasury Shares history spans 10 years, with the latest figure at $98.9 million for Q3 2024.

  • For Q3 2024, Treasury Shares rose 24.09% year-over-year to $98.9 million; the TTM value through Sep 2024 reached $98.9 million, up 24.09%, while the annual FY2023 figure was $85.9 million, 28.59% up from the prior year.
  • Treasury Shares for Q2 2024 was $169571.0 at Avanos Medical, down from $342680.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $2.1 million in Q4 2022 and bottomed at $169571.0 in Q2 2024.
  • The 5-year median for Treasury Shares is $551081.0 (2021), against an average of $700593.0.
  • The largest annual shift saw Treasury Shares rose 6.98% in 2020 before it skyrocketed 538.46% in 2022.
  • A 5-year view of Treasury Shares shows it stood at $9.8 million in 2020, then skyrocketed by 117.35% to $21.3 million in 2021, then skyrocketed by 213.62% to $66.8 million in 2022, then grew by 28.59% to $85.9 million in 2023, then increased by 15.13% to $98.9 million in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Treasury Shares are $98.9 million (Q3 2024), $98.5 million (Q2 2024), and $95.0 million (Q1 2024).